{"id":8972,"date":"2025-12-09T23:02:24","date_gmt":"2025-12-09T23:02:24","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/12\/09\/ash-jandj-multiple-myeloma-and-cdc-sickle-cell-data\/"},"modified":"2025-12-09T23:02:24","modified_gmt":"2025-12-09T23:02:24","slug":"ash-jandj-multiple-myeloma-and-cdc-sickle-cell-data","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/12\/09\/ash-jandj-multiple-myeloma-and-cdc-sickle-cell-data\/","title":{"rendered":"STAT+: J&amp;J\u2019s two-drug combo blocked tumors in advanced multiple myeloma"},"content":{"rendered":"\n<div>STAT+: J&#038;J\u2019s two-drug combo blocked tumors in advanced multiple myeloma<\/div>\n<p> \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>This is the web version of ASH in 30 Seconds, STAT\u2019s report from the American Society of Hematology meeting. <\/em><\/p>\n<p>And on the last day of ASH, the sun shone once again. Thanks for joining us on this hematology-oncology journey. We hope you\u2019ve enjoyed our coverage. Until next year, in New Orleans!<\/p>\n<h2>J&amp;J\u2019s \u2018Tec-Dara\u2019 combo shines in multiple myeloma study<\/h2>\n<p>A two-drug regimen from Johnson &amp; Johnson showed an unprecedented tumor-progression benefit compared to the standard of care for patients with relapsed or refractory multiple myeloma, according to results from a Phase 3 study presented today.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/12\/09\/ash-jandj-multiple-myeloma-and-cdc-sickle-cell-data\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein, Angus Chen, Damian Garde, and Katherine MacPhail<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/12\/09\/ash-jandj-multiple-myeloma-and-cdc-sickle-cell-data\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: J&#038;J\u2019s two-drug combo blocked tumors in advanced multiple myeloma This is the web version of ASH in 30 Seconds, STAT\u2019s report from the American Society of Hematology meeting. And on the last day of ASH, the sun shone once again. Thanks for joining us on this hematology-oncology journey. We hope you\u2019ve enjoyed our coverage. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4374,2194,2159,1428,2176,2564,2565,2152],"tags":[2150],"class_list":["post-8972","post","type-post","status-publish","format-standard","hentry","category-ash","category-biotech","category-cancer","category-health","category-pharma","category-rare-disease","category-sickle-cell","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8972"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=8972"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8972\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=8972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=8972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=8972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}